


Docket Number: 037003-0275478

PATENT APPLICATION

Client Reference: 1999-30-0466A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 3 1 2003

In Re The Application of HANNA et al.

Group Art Unit: 1644

Application No.: 09/435,992

Examiner: Phillip Gambel

Filed: November 8, 1999

Confirmation No.: 5990

For: TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND RADIOTHERAPY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance. Payment of the requisite fee under 37 CFR 1.17(p) is enclosed.

Respectfully Submitted,

01/08/2004 AWONDAF1 00000037 033975 09435992

02 FC:1806 180.00 DA

Thomas A. Cawley, Jr., Ph.D.  
Registration Number 40,944  
Customer Number: 00909

Date: December 31, 2003

PILLSBURY WINTHROP LLP  
Telephone: (703) 905-2000  
Facsimile: (703) 905-2500  
P.O. Box 10500  
McLean, VA 22102  
TAC/JBM:ntb

FORM PTO-1449 (modified)  
 To: U.S. Department of Commerce  
 (PW FORM PAT-1449)  
 Patent and Trademark Office

Atty. Dkt. No.	M#	Client Ref.
	0275478	1999-30-0466A

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**



Date: December 31, 2003

Page **1** of **1**

Applicant: HANNA et al.

Appln. No.: 09/435,992

Filing Date: November 8, 1999

Examiner: Phillip Gabel Group Art Unit: 1644

**U.S. PATENT DOCUMENTS**

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	AR	6,183,744 B1	02/2001	GOLDENBERG			
	BR	6,306,393 B1	10/2001	GOLDENBERG			
	CR						
	DR						
	ER						
	FR						

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	GR	0892643 B1	06/2002	EP	LARSEN et al.		
	HR						
	IR						
	JR						
	KR						
	LR						

**OTHER**

	MR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83.
	NR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, p. 271, Abstract No. 1051.
	OR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37<sup>th</sup> Annual Meeting</i> , p. 852, Abstract No. 622.
	PR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.
	QR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.
	RR	Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp. 1696-1711.
	SR	Jensen, et al., "Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDE-C2B8, rituximab)," 1998, <i>Ann Hematol</i> , 77:89-91.
	TR	

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.